These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

527 related articles for article (PubMed ID: 2529358)

  • 1. Immunologic monitoring with Orthoclone OKT3 therapy.
    Schroeder TJ; First MR; Hurtubise PE; Marmer DJ; Martin DM; Mansour ME; Melvin DB
    J Heart Transplant; 1989; 8(5):371-80. PubMed ID: 2529358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful retreatment of allograft rejection with OKT3.
    First MR; Schroeder TJ; Hurtubise PE; Mansour ME; Penn I; Munda R; Balistreri WF; Alexander JW; Melvin DB; Fidler JP
    Transplantation; 1989 Jan; 47(1):88-91. PubMed ID: 2521410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylactic use of OKT3 in immunologic high-risk cadaver renal transplant recipients.
    Schroeder TJ; First MR; Mansour ME; Alexander JW; Penn I
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):14-8. PubMed ID: 2510506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. OKT3 escalating dose regimens provide effective therapy for renal allograft rejection.
    Woodle ES; Bruce DS; Josephson M; Cronin D; Newell KA; Millis JM; Piper JB; O'Laughlin R; Thistlethwaite JR
    Clin Transplant; 1996 Aug; 10(4):389-95. PubMed ID: 8884115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Failure of orthoclone OKT3 retreatment in a pancreas transplant recipient with antimurine antibodies.
    Schroeder TJ; Munda R; Pedersen SH; Hurtubise PE; Alexander JW; First MR
    J Clin Lab Anal; 1990; 4(2):99-101. PubMed ID: 2313476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T10B9.1A-31 anti-T-cell monoclonal antibody: preclinical studies and clinical treatment of solid organ allograft rejection.
    Waid TH; Lucas BA; Amlot P; Janossy G; Yacoub M; Cammisuli S; Jezek D; Rhoades J; Brown S; Thompson JS
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):61-70. PubMed ID: 2479265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunologic monitoring of OKT3 induction therapy in cardiac allograft recipients.
    Toyoda M; Galfayan K; Wachs K; Czer L; Jordan SC
    Clin Transplant; 1995 Dec; 9(6):472-80. PubMed ID: 8645891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Muromonab CD-3: a review of its pharmacology, pharmacokinetics, and clinical use in transplantation.
    Hooks MA; Wade CS; Millikan WJ
    Pharmacotherapy; 1991; 11(1):26-37. PubMed ID: 1902291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The reuse of OKT3 after previous rejection or induction therapy in cadaveric renal transplantation.
    Shield CF; Hughes JD
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):35-8. PubMed ID: 2510509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective comparison of murine monoclonal CD-3 (OKT3) antibody-based and equine antithymocyte globulin-based rejection prophylaxis in cardiac transplantation. Decreased rejection and less corticosteroid use with OKT3.
    Renlund DG; O'Connell JB; Gilbert EM; Hammond ME; Burton NA; Jones KW; Karwande SV; Doty DB; Menlove RL; Herrick CM
    Transplantation; 1989 Apr; 47(4):599-605. PubMed ID: 2523099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical experience with Muromonab-CD3 monoclonal antibody (OKT3) in heart transplantation.
    Macris MP; Frazier OH; Lammermeier D; Radovancevic B; Duncan JM
    J Heart Transplant; 1989; 8(4):281-7. PubMed ID: 2504894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term follow-up of heart transplant recipients treated with murine antihuman mature T cell monoclonal antibody (OKT3): the Loyola experience.
    Costanzo-Nordin MR; O'Sullivan EJ; Hubbell EA; Zucker MJ; Pifarre R; McManus BM; Winters GL; Scanlon PJ; Robinson JA
    J Heart Transplant; 1989; 8(4):288-95. PubMed ID: 2504895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reexposure to OKT3 in renal allograft recipients.
    Mayes JT; Thistlethwaite JR; Stuart JK; Buckingham MR; Stuart FP
    Transplantation; 1988 Feb; 45(2):349-53. PubMed ID: 3278428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overview of the development of Orthoclone OKT3: monoclonal antibody for therapeutic use in transplantation.
    Goldstein G
    Transplant Proc; 1987 Apr; 19(2 Suppl 1):1-6. PubMed ID: 3105134
    [No Abstract]   [Full Text] [Related]  

  • 15. Mouse antibody-coated lymphocytes during OKT3 therapy in liver transplantation.
    Broughan TA; Valenzuela R; Escorcia E; Secic M; Vogt DP
    Clin Transplant; 1994 Oct; 8(5):488-91. PubMed ID: 7819617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The OKT3 immunosuppressive effect. In situ antigenic modulation of human graft-infiltrating T cells.
    Caillat-Zucman S; Blumenfeld N; Legendre C; Noel LH; Bach JF; Kreis H; Chatenoud L
    Transplantation; 1990 Jan; 49(1):156-60. PubMed ID: 2137271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An overview of the use of the monoclonal antibody OKT3 in renal transplantation.
    Norman DJ
    Transplant Proc; 1988 Dec; 20(6):1248-52. PubMed ID: 2974204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. OKT3 resistant rejection in liver transplant patients.
    Sutherland F; Lazarovits A; Aboujaoude M; Grant D; Ghent C; Sommerauer J; Wall W
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1413-4. PubMed ID: 1824898
    [No Abstract]   [Full Text] [Related]  

  • 19. Monoclonal antibody OKT3 therapy in pediatric kidney transplant recipients.
    Leone MR; Barry JM; Alexander SR; Melvin T; Striegel J; Reller K; Henell KR; Kimball J; Funnell MB; Goldstein G
    J Pediatr; 1990 May; 116(5):S86-91. PubMed ID: 2139465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The incidence of antibody formation to OKT3 consequent to its use in organ transplantation.
    Carey G; Lisi PJ; Schroeder TJ
    Transplantation; 1995 Jul; 60(2):151-8. PubMed ID: 7624957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.